Company Overview

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for metabolic and endocrinologic diseases. The company operates within the biotechnology and pharmaceutical research industry, with an emphasis on conditions that have large patient populations and significant unmet medical needs, particularly obesity, metabolic dysfunction–associated steatohepatitis (MASH), and related cardiometabolic disorders.

The company’s primary value drivers are its internally developed drug candidates targeting validated biological pathways involved in metabolism. Terns is positioned as a precision-focused metabolic disease developer, emphasizing oral, small-molecule therapeutics rather than injectable biologics, which it views as a potential differentiation in patient convenience and long-term adherence. Terns Pharmaceuticals was founded in 2017 and became a publicly traded company following its initial public offering in 2021, using the proceeds to advance its clinical pipeline and expand internal R&D capabilities.

Business Operations

Terns Pharmaceuticals operates as a single-reportable-segment company focused on drug discovery and clinical development. Its core operations include preclinical research, clinical trial execution, regulatory strategy, and manufacturing coordination through third-party contractors. The company does not currently generate product revenue; its activities are funded primarily through equity financing and cash reserves raised in public and private markets.

The company’s pipeline includes oral small-molecule candidates targeting glucagon-like peptide-1 (GLP-1), glucagon receptors, and thyroid hormone receptor beta (THR-β). Terns relies on a network of contract research organizations and manufacturing partners for clinical trials and drug production, while retaining strategic control over intellectual property and development decisions. There are no disclosed revenue-generating subsidiaries, and operations are concentrated on advancing proprietary assets toward later-stage clinical development.

Strategic Position & Investments

Terns Pharmaceuticals’ strategic direction centers on building a differentiated portfolio of oral therapies for obesity and related metabolic diseases, with a focus on scalability and combination potential. Growth initiatives are driven by advancing lead candidates through mid-stage clinical trials and selectively expanding the pipeline through internal discovery rather than large-scale acquisitions.

The company has made targeted investments in clinical programs rather than acquiring established commercial assets, reflecting its early- to mid-stage development profile. Its most notable investments are internal, including continued capital allocation toward its obesity and MASH programs. Terns has not announced material acquisitions or joint ventures but has entered into selective licensing and research-related agreements to support discovery efforts. Its strategic positioning emphasizes long-term value creation through internally generated intellectual property in high-growth metabolic sectors.

Geographic Footprint

Terns Pharmaceuticals is headquartered in the United States, with its principal executive offices located in California. Its operational footprint is primarily domestic, focused on research, development, and corporate management activities within the U.S. Clinical trials, however, are conducted across multiple regions, including North America and select international locations, depending on study design and regulatory requirements.

While the company does not maintain significant physical infrastructure outside the United States, it has an international operational presence through global clinical trial sites and third-party service providers. This structure allows Terns to access diverse patient populations and comply with international regulatory standards without establishing permanent overseas subsidiaries.

Leadership & Governance

Terns Pharmaceuticals is led by an executive team with experience in pharmaceutical development, clinical research, and corporate strategy. The leadership philosophy emphasizes scientific rigor, disciplined capital allocation, and a focus on high-impact metabolic targets supported by clinical data.

Key executives include:

• Andrew A. Lazar – President, Chief Executive Officer, and Director
• Erik Makinen – Chief Financial Officer
• Sarah J. Hong – Chief Medical Officer
• Shannon K. Su – Chief Scientific Officer

The board of directors provides governance oversight and strategic guidance, with experience spanning biotechnology, finance, and public company leadership. The company’s governance framework aligns with U.S. public company standards and emphasizes risk management, clinical integrity, and shareholder accountability.